Gentbrugge, Belgium

Bart Walcarius

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bart Walcarius: Innovator in Immunoglobulin Production

Introduction

Bart Walcarius is a notable inventor based in Gentbrugge, Belgium. He has made significant contributions to the field of biotechnology, particularly in the production of immunoglobulin single variable domains. His innovative methods have the potential to enhance the efficiency and quality of therapeutic proteins.

Latest Patents

Walcarius holds a patent for a "Method for the production of immunoglobulin single variable domains." This patent outlines methods for expressing immunoglobulin variable domains that are secreted into the culture medium. The techniques described in the patent aim to produce homogeneous immunoglobulin variable domains, significantly reducing or eliminating product-related variants that contain redundant amino acid residues derived from the secretion signal.

Career Highlights

Bart Walcarius is associated with Ablynx N.V., a company known for its pioneering work in the development of nanobodies and other therapeutic proteins. His role at Ablynx has allowed him to apply his expertise in immunology and biotechnology to advance the company's research and development efforts.

Collaborations

Walcarius has collaborated with esteemed colleagues, including Ann Brigé and Peter Schotte. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of biotechnology.

Conclusion

Bart Walcarius is a distinguished inventor whose work in immunoglobulin production has the potential to impact the biotechnology industry significantly. His contributions, particularly through his patent, demonstrate his commitment to advancing therapeutic protein production.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…